^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD79B mutation

i
Other names: CD79B, B-Cell Antigen Receptor Complex-Associated Protein Beta Chain, CD79b Molecule, Immunoglobulin-Associated Beta, Immunoglobulin-Associated B29 Protein, B-Cell-Specific Glycoprotein B29, Ig-Beta, IGB, B29, CD79b Antigen (Immunoglobulin-Associated Beta), CD79B Antigen (Immunoglobulin-Associated Beta), CD79b Antigen, AGM6
Entrez ID:
Related biomarkers:
Phase 2
BeiGene
Recruiting
Last update posted :
05/07/2024
Initiation :
08/11/2021
Primary completion :
12/30/2024
Completion :
12/30/2024
CD79B
|
CD79B mutation • CD79B mutation
|
Brukinsa (zanubrutinib)
Phase 2
Fudan University
Recruiting
Last update posted :
03/22/2022
Initiation :
01/04/2022
Primary completion :
01/04/2024
Completion :
01/04/2026
TP53 • MYC • MYD88 • CD79B
|
TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
Phase 2
Chinese Academy of Medical Sciences
Not yet recruiting
Last update posted :
08/06/2021
Initiation :
10/01/2021
Primary completion :
04/01/2022
Completion :
07/01/2025
CD20 • MYD88 • CD79B • CD79A
|
CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation
|
Imbruvica (ibrutinib) • Rituxan (rituximab)
Phase N/A
University Hospital, Bordeaux
Unknown status
Last update posted :
04/29/2020
Initiation :
02/19/2019
Primary completion :
05/01/2020
Completion :
05/01/2020
BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1
|
CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation